Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
Elizabeth E Zumbrun, Chengzi I Kaku, Lukas Dillinger, Samantha E Zak, Ana I Kuehne, Russel R Bakken, Jeffrey W Koehler, Korey L Delp, Christopher P Stefan, Raina Kumar, Jeffrey R Kugelman, Alicia M Moreau, Xiankun Zeng, John M Dye, Andrew S Herbert, Kristin Narayan, Laura M Walker
Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01353-22
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.
References
Andrews, Stowe, Kirsebom, Toffa, Rickeard et al., COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, N Engl J Med,
doi:10.1056/NEJMoa2119451Dejnirattisai, Huo, Zhou, Zahradník, Supasa et al., SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses,
doi:10.1016/j.cell.2021.12.046Imai, Iwatsuki-Horimoto, Hatta, Loeber, Halfmann et al., Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2009799117Kaku, Narayan, Schmidt, Engler, Li et al., ADG20, a half-life-extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants
Liu, Ginn, Dejnirattisai, Supasa, Wang et al., Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum, Cell,
doi:10.1016/j.cell.2021.06.020Liu, Iketani, Guo, Chan, Wang et al., Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2, Nature,
doi:10.1038/s41586-021-04388-0Martinez, Schäfer, Gobeil, Li, De La Cruz et al., A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice, Sci Transl Med,
doi:10.1126/scitranslmed.abj7125Osterrieder, Bertzbach, Dietert, Abdelgawad, Vladimirova et al., Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters, Viruses,
doi:10.3390/v12070779Rappazzo, Tse, Kaku, Wrapp, Sakharkar et al., Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody, Science,
doi:10.1126/science.abf4830Rogers, Zhao, Huang, Beutler, Burns et al., Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model, Science,
doi:10.1126/science.abc7520Vegivinti, Evanson, Lyons, Akosman, Barrett et al., Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials, BMC Infect Dis,
doi:10.1186/s12879-022-07068-0Who, Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update, WHO
{ 'DOI': '10.1128/aac.01353-22',
'ISSN': ['0066-4804', '1098-6596'],
'URL': 'http://dx.doi.org/10.1128/aac.01353-22',
'abstract': '<jats:p>Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have '
'broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) '
'variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden '
'hamster and rhesus macaque models, prophylactic administration of a single dose of '
'adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent '
'manner, as measured by significant reductions in lung viral load and virus-induced lung '
'pathology, and by inhibition of viral replication in the upper and lower respiratory '
'tract.</jats:p>',
'alternative-id': ['10.1128/aac.01353-22'],
'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'},
'label': 'Received',
'name': 'received',
'order': 0,
'value': '2022-10-07'},
{ 'group': {'label': 'Publication History', 'name': 'publication_history'},
'label': 'Accepted',
'name': 'accepted',
'order': 1,
'value': '2022-11-30'},
{ 'group': {'label': 'Publication History', 'name': 'publication_history'},
'label': 'Published',
'name': 'published',
'order': 2,
'value': '2022-12-15'}],
'author': [ { 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Zumbrun',
'given': 'Elizabeth E.',
'sequence': 'first'},
{ 'affiliation': [{'name': 'Adimab LLC, Lebanon, New Hampshire, USA'}],
'family': 'Kaku',
'given': 'Chengzi I.',
'sequence': 'additional'},
{ 'affiliation': [{'name': 'Invivyd, Inc., Waltham, Massachusetts, USA'}],
'family': 'Dillinger',
'given': 'Lukas',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Zak',
'given': 'Samantha E.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Kuehne',
'given': 'Ana I.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Bakken',
'given': 'Russel R.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Koehler',
'given': 'Jeffrey W.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Delp',
'given': 'Korey L.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Stefan',
'given': 'Christopher P.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Kumar',
'given': 'Raina',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Kugelman',
'given': 'Jeffrey R.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Moreau',
'given': 'Alicia M.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Zeng',
'given': 'Xiankun',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Dye',
'given': 'John M.',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'U.S. Army Medical Research Institute of Infectious Diseases, '
'Frederick, Maryland, USA'}],
'family': 'Herbert',
'given': 'Andrew S.',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0002-7977-4783',
'affiliation': [{'name': 'Invivyd, Inc., Waltham, Massachusetts, USA'}],
'authenticated-orcid': True,
'family': 'Narayan',
'given': 'Kristin',
'sequence': 'additional'},
{ 'affiliation': [{'name': 'Invivyd, Inc., Waltham, Massachusetts, USA'}],
'family': 'Walker',
'given': 'Laura M.',
'sequence': 'additional'}],
'container-title': 'Antimicrobial Agents and Chemotherapy',
'container-title-short': 'Antimicrob Agents Chemother',
'content-domain': {'crossmark-restriction': True, 'domain': ['journals.asm.org']},
'created': { 'date-parts': [[2022, 12, 15]],
'date-time': '2022-12-15T14:02:42Z',
'timestamp': 1671112962000},
'deposited': { 'date-parts': [[2023, 1, 24]],
'date-time': '2023-01-24T14:05:22Z',
'timestamp': 1674569122000},
'indexed': {'date-parts': [[2023, 7, 25]], 'date-time': '2023-07-25T16:52:51Z', 'timestamp': 1690303971674},
'is-referenced-by-count': 1,
'issue': '1',
'issued': {'date-parts': [[2023, 1, 24]]},
'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023, 1, 24]]}},
'language': 'en',
'license': [ { 'URL': 'https://doi.org/10.1128/ASMCopyrightv2',
'content-version': 'vor',
'delay-in-days': 0,
'start': { 'date-parts': [[2023, 1, 24]],
'date-time': '2023-01-24T00:00:00Z',
'timestamp': 1674518400000}},
{ 'URL': 'https://journals.asm.org/non-commercial-tdm-license',
'content-version': 'tdm',
'delay-in-days': 0,
'start': { 'date-parts': [[2023, 1, 24]],
'date-time': '2023-01-24T00:00:00Z',
'timestamp': 1674518400000}}],
'link': [ { 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.01353-22',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.01353-22',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'member': '235',
'original-title': [],
'prefix': '10.1128',
'published': {'date-parts': [[2023, 1, 24]]},
'published-print': {'date-parts': [[2023, 1, 24]]},
'publisher': 'American Society for Microbiology',
'reference': [ { 'key': 'e_1_3_3_2_2',
'unstructured': 'WHO. 2022. Coronavirus disease (COVID-19) weekly epidemiological update '
'and weekly operational update. WHO Geneva Switzerland. Available from '
'https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.'},
{'DOI': '10.1056/NEJMoa2119451', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_3_2'},
{'DOI': '10.1038/s41586-021-04388-0', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_4_2'},
{'DOI': '10.1186/s12879-022-07068-0', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_5_2'},
{'DOI': '10.1016/j.cell.2021.03.055', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_6_2'},
{'DOI': '10.1016/j.cell.2021.06.020', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_7_2'},
{'DOI': '10.1126/science.abf4830', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_8_2'},
{'DOI': '10.1016/j.cell.2021.12.046', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_9_2'},
{ 'author': 'Kaku CI',
'key': 'e_1_3_3_10_2',
'unstructured': 'Kaku CI, Narayan K, Schmidt P, Engler F, Li Y, Walker LM. 2022. ADG20, a '
'half-life-extended monoclonal antibody in development for the prevention '
'and treatment of COVID-19, demonstrated broad in vitro neutralisation '
'against SARS-CoV-2 variants. Abstract. European Congress of Clinical '
'Microbiology & Infectious Diseases (ECCMID), Lisbon, Portugal.',
'volume-title': 'ADG20, a half-life-extended monoclonal antibody in development for the '
'prevention and treatment of COVID-19, demonstrated broad in vitro '
'neutralisation against SARS-CoV-2 variants.',
'year': '2022'},
{ 'DOI': '10.1126/scitranslmed.abj7125',
'doi-asserted-by': 'publisher',
'key': 'e_1_3_3_11_2'},
{ 'author': 'National Research Council (US) Committee for the Update of the Guide for the '
'Care and Use of Laboratory Animals',
'edition': '8',
'key': 'e_1_3_3_12_2',
'unstructured': 'National Research Council (US) Committee for the Update of the Guide for '
'the Care and Use of Laboratory Animals. 2011. Guide for the care and use '
'of laboratory animals, 8th ed. National Academies Press, Washington, DC. '
'Available from https://www.ncbi.nlm.nih.gov/books/NBK54050/.',
'volume-title': 'Guide for the care and use of laboratory animals',
'year': '2011'},
{'DOI': '10.1073/pnas.2009799117', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_13_2'},
{'DOI': '10.3390/v12070779', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_14_2'},
{'DOI': '10.1038/s41586-020-2342-5', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_15_2'},
{'DOI': '10.1126/science.abc7520', 'doi-asserted-by': 'publisher', 'key': 'e_1_3_3_16_2'}],
'reference-count': 15,
'references-count': 15,
'relation': {},
'resource': {'primary': {'URL': 'https://journals.asm.org/doi/10.1128/aac.01353-22'}},
'score': 1,
'short-title': [],
'source': 'Crossref',
'subject': ['Infectious Diseases', 'Pharmacology (medical)', 'Pharmacology'],
'subtitle': [],
'title': 'Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 '
'in Hamster and Non-Human Primate Models of COVID-19',
'type': 'journal-article',
'update-policy': 'http://dx.doi.org/10.1128/asmj-crossmark-policy-page',
'volume': '67'}
